A Randomized Phase II Trial of Fulvestrant and Palbociclib in Combination With Copanlisib (FPC) Versus Fulvestrant and Palbociclib Alone (FP) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FPC vs FP)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2018
Price : $35 *
At a glance
- Drugs Copanlisib (Primary) ; Fulvestrant (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2018 Planned End Date changed from 1 Mar 2020 to 9 Aug 2018.
- 13 Aug 2018 Planned primary completion date changed from 1 Mar 2020 to 8 Aug 2018.